Clinical Trials Epilepsy Policy Safety 
Cannabis Law Report
JULY 13, 2019
clinical trials have been made by Members of Parliament. After months of interviews and weighing-up reams of evidence The House of Commons Health and Social Care Committee has issued its latest report; ‘ Drugs policy: medicinal cannabis’. CBD Testers.co However the problem in the U.K.
The Cannigma
JUNE 15, 2021
The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. The perception that CBD is a wonder-drug version of cannabis — particularly known for its uses to treat epilepsy — that doesn’t get you high.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 15, 2019
There is even published research, derived from clinical trials, on the potential uses of cannabinoids to manage seizures and epilepsy, cited the ministries. The ministries asserted that the policies are underpinned by research.
Cannabis Law Report
JUNE 1, 2021
Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding. Cautionary Note on Forward-Looking Statements.
Canna Law Blog
APRIL 17, 2020
THC binds to the CB1 receptors, but the way that CBD interacts with ECS is not fully understood in humans or animals, despite the fact that Epidiolex has been approved as a drug for treating epilepsy. Since then, many other states, including Utah and Texas have adopted similar labeling standards, making Indiana a leader in Hemp CBD policy.
Project CBD
FEBRUARY 28, 2023
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Available at: www.fda.gov/media/131878/download.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Refractory paediatric epilepsy. At the same time, the outlook on cannabis research data is largely positive. Conclusions.
Expert insights. Personalized for you.
40 
Let's personalize your content